Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/8/2022 | $4.00 | Buy | Canaccord Genuity |
| 10/14/2022 | $5.50 | Outperform | Credit Suisse |
LEXINGTON, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ:GRNA) ("GreenLight" or the "Company") today announced the closing of its previously announced merger with SW MergerCo, Inc. ("Merger Sub") and SW ParentCo, Inc. ("Parent"), pursuant to which Merger Sub merged with and into GreenLight with GreenLight surviving as a wholly-owned subsidiary of Parent (the "Merger"). Following the completion of the Merger, shares of GreenLight common stock, par value $0.0001 per share, and GreenLight warrants ceased trading on the NASDAQ Global Market (the "NASDAQ") before market open on July 24, 2023, and will no longer be listed for trading on the NASDAQ. Each r
LEXINGTON, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ:GRNA) ("GreenLight" or the "Company") today announced that it is initiating the final steps in closing its previously announced merger with SW MergerCo, Inc. ("Merger Sub") and SW ParentCo, Inc ("Parent"). Following the completion of the Merger, shares of GreenLight common stock are expected to cease trading on the NASDAQ Global Market ("NASDAQ") after market close on July 20, 2023, and will no longer be listed for trading on the NASDAQ. Merger Sub's tender offer (the "Offer") to purchase any and all outstanding shares of GreenLight's common stock (other than shares of GreenLight common stock (
NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ:GRNA) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of GRNA to a group of buyers led by Fall Line Capital, LLC for $0.30 per share in cash. If you are a GRNA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Arlington Asset Investment Corp. (NYSE:AAIC) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connect
Canaccord Genuity initiated coverage of GreenLight Biosciences with a rating of Buy and set a new price target of $4.00
Credit Suisse initiated coverage of GreenLight Biosciences with a rating of Outperform and set a new price target of $5.50
LEXINGTON, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ:GRNA) ("GreenLight" or the "Company") today announced that it is initiating the final steps in closing its previously announced merger with SW MergerCo, Inc. ("Merger Sub") and SW ParentCo, Inc ("Parent"). Following the completion of the Merger, shares of GreenLight common stock are expected to cease trading on the NASDAQ Global Market ("NASDAQ") after market close on July 20, 2023, and will no longer be listed for trading on the NASDAQ. Merger Sub's tender offer (the "Offer") to purchase any and all outstanding shares of GreenLight's common stock (other than shares of GreenLight common stock (
4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)
3 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)
4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)
15-12G - GreenLight Biosciences Holdings, PBC (0001822691) (Filer)
8-K/A - GreenLight Biosciences Holdings, PBC (0001822691) (Filer)
EFFECT - GreenLight Biosciences Holdings, PBC (0001822691) (Filer)
SC 13D/A - GreenLight Biosciences Holdings, PBC (0001822691) (Subject)
SC 13D/A - GreenLight Biosciences Holdings, PBC (0001822691) (Subject)
SC 13D/A - GreenLight Biosciences Holdings, PBC (0001822691) (Subject)